Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 89 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $748 | +147.7% | 137,299 | +208.3% | 0.06% | +113.3% |
| Q2 2023 | $302 | -62.7% | 44,534 | -72.4% | 0.03% | -62.5% |
| Q1 2023 | $809 | +67.1% | 161,509 | +62.9% | 0.08% | +33.3% |
| Q4 2022 | $484 | -100.0% | 99,160 | +43.1% | 0.06% | -57.4% |
| Q4 2021 | $1,124,000 | +322.6% | 69,311 | +593.1% | 0.14% | +840.0% |
| Q3 2018 | $266,000 | – | 10,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |